Mar 02, 2020 / 04:20PM GMT
Christopher DelOrefice - Johnson & Johnson - VP of IR
(technical difficulty)
measures, please refer to our SEC filings, in particular our 10-K, which discuss the risks and uncertainties around forward-looking statements, as well as our website at investor.jnj.com for reconciliations to comparable GAAP measures. Finally, any remarks regarding financial performance represent results through and including the fourth quarter of 2019. Thank you.
Questions and Answers:
Joshua Thomas Jennings - Cowen and Company, LLC, Research Division - MD & Senior Research AnalystThank you. Well, I mean, I think everyone -- the coronavirus is in front of everyone's mind, and as it should be. We're in a little bit an unknown era here in terms of how severe things could get. We've seen what's happened in China, and there's been some movement.
But I think maybe to start off on a positive note, I think J&J should be commended for the work it's doing just in the vaccine development and also I think your looking -- or screening library of antivirals.
Trustpilot
